Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company that regularly issues news on its business segments, financing activities, partnerships and product pipeline. As an ophthalmic goods manufacturer with operations in vision care, surgical products and ophthalmic pharmaceuticals, the company’s announcements cover a broad range of topics relevant to investors and those following the eye health sector.
News updates include financial results, such as quarterly revenue performance across the Vision Care, Surgical and Pharmaceuticals segments, as well as details on operating income, adjusted metrics and guidance ranges. The company also uses press releases to outline strategic plans and multi-year financial targets, describe its product pipeline in areas like dry eye, glaucoma, ocular surface pain and age-related macular degeneration, and highlight clinical-stage programs and anticipated launches across consumer, pharmaceutical, surgical and contact lens businesses.
Bausch + Lomb’s news flow also features information on capital structure and liquidity, including amendments to its credit agreement, new term loan tranches, revolving credit facilities and senior secured notes offerings, along with the intended use of proceeds for refinancing existing debt. Governance and leadership developments, such as board appointments, committee assignments and changes related to director nomination agreements, are disclosed through current reports and accompanying press releases.
In addition, the company issues news about partnerships and initiatives in eye health, including collaborations with organizations focused on glaucoma research and awareness, and sustainability programs like the ONE by ONE Recycling Program and the Every Contact Counts program. For readers tracking BLCO, this news page aggregates these updates so they can review company communications on financial performance, strategic direction, product development, governance and eye health initiatives in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced 25 presentations during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. This includes 21 podium presentations and four poster presentations, with highlights on the new StableVisc™ device and the LOTEMAX® ophthalmic gel. Bausch + Lomb will also sponsor two educational events focusing on dry eye disease and the IC-8 Apthera lens. Approximately 18 million Americans are affected by dry eye disease, emphasizing the significance of the topics discussed. Notably, new data from the ARMOR study will be presented, aiming to address antibiotic resistance in ocular microorganisms.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) held its 2023 annual meeting on April 24, 2023, where shareholders elected 10 directors. Key voting results included:
- Nathalie Bernier: 344,100,848 votes for, 124,733 against
- Richard U. De Schutter: 344,094,979 votes for, 130,602 against
- Gary Hu: 344,016,782 votes for, 208,799 against
- Brett Icahn: 344,072,707 votes for, 152,874 against
In addition to the elections, shareholders approved the advisory compensation of executives, an amendment to increase shares under the 2022 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent accounting firm until the 2024 annual meeting. The results will be filed with the SEC.
Bausch + Lomb Corporation has launched two new ophthalmic viscosurgical devices (OVDs), StableVisc and TotalVisc, aimed at enhancing cataract surgery outcomes. These devices provide dual-action protection, addressing concerns about free radical damage during surgical procedures. StableVisc maintains anterior chamber space, while TotalVisc combines both StableVisc and ClearVisc for comprehensive ocular protection.
With a fill volume of one milliliter, StableVisc leads its segment, reducing the need for multiple packs during surgery. The devices contain sodium hyaluronate and sorbitol, offering a strong barrier against free radicals, which can lead to post-surgical complications.
This launch positions Bausch + Lomb as a leader in innovative solutions for eye health, particularly in the competitive cataract surgery market.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced eight scientific poster presentations at the ARVO annual meeting in New Orleans from April 23-27, 2023. Highlights include results from the 12-month KALAHARI safety extension study of NOV03 (perfluorohexyloctane) and data on XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use. Notable studies presented include antibiotic resistance patterns from the ARMOR surveillance study and evaluations on intraocular lens pipeline programs. Bausch + Lomb remains committed to advancing research and innovation in eye health to meet patient needs.
Bausch + Lomb Corporation (BLCO) has announced significant achievements in its eye care recycling initiatives. The ONE by ONE and Biotrue® Eye Care Recycling programs have successfully recycled a total of 65.8 million units, equivalent to 397,194 pounds of waste, since their inception. The ONE by ONE program, launched in 2016, has collected over 65 million used contact lenses and related materials, while the Biotrue® program, initiated in 2021, has gathered more than 440,000 eye drop units and lens cases. With nearly 13,000 eye care practices participating, these programs aim to mitigate plastic waste and contribute to sustainability efforts. Bausch + Lomb collaborates with TerraCycle for recycling operations, emphasizing their commitment to environmental health.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will release its first-quarter 2023 financial results on May 3, 2023, at 8:00 a.m. ET. The company will conduct a conference call and live webcast to discuss these results and provide a business update. Interested parties can access the webcast through the Investor Relations section of the Bausch + Lomb website. Additionally, a replay of the conference call will be available until May 17, 2023.
Bausch + Lomb operates globally with over 400 products in its portfolio, emphasizing eye health. Founded in 1853, the company employs approximately 13,000 individuals and maintains a presence in nearly 100 countries.